Praesto 70 CH1 Pre-clinical Modeling Application Note

This application note presents a technical study on the Praesto 70 CH1 resin, focusing on its economic benefits in the biotherapeutic industry. The document outlines the challenges associated with new biotherapeutic molecules, particularly in purifying complex products while maintaining yield and stability. It details the comparative analysis of Praesto 70 CH1 against traditional Protein A and other CH1-binding resins, emphasizing its higher capacity and longer lifecycle. The study includes dynamic binding capacity assessments, impurity removal efficiency, and operational parameters for resin performance. Additionally, it discusses the modeling of cost, productivity, and sustainability benefits, using data from various titers in a bioreactor setup. The findings suggest that Praesto 70 CH1 can significantly enhance the purification process for asymmetric bispecific antibodies by effectively differentiating between product-related impurities, thus improving overall efficiency and robustness in biotherapeutic production.